These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 31040845)

  • 21. Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess.
    Pérez D; Tincani A; Serrano M; Shoenfeld Y; Serrano A
    Lupus; 2018 Feb; 27(2):177-178. PubMed ID: 29067871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA expression in antiphospholipid syndrome: a systematic review and microRNA target genes analysis.
    Muhammad Shazwan S; Muhammad Aliff M; Asral Wirda AA; Hayati AR; Maizatul Azma M; Nur Syahrina AR; Nazefah AH; Jameela S; Nur Fariha MM
    Malays J Pathol; 2016 Dec; 38(3):273-283. PubMed ID: 28028298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiphospholipid Syndrome and the Kidney.
    Sciascia S; Baldovino S; Schreiber K; Solfietti L; Roccatello D
    Semin Nephrol; 2015 Sep; 35(5):478-86. PubMed ID: 26573550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis.
    Reynaud Q; Lega JC; Mismetti P; Chapelle C; Wahl D; Cathébras P; Laporte S
    Autoimmun Rev; 2014 Jun; 13(6):595-608. PubMed ID: 24418303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome.
    Montalvão S; Elídio PS; da Silva Saraiva S; de Moraes Mazetto B; Colella MP; de Paula EV; Appenzeller S; Annichino-Bizzacchi J; Orsi FA
    Thromb Res; 2016 Dec; 148():32-37. PubMed ID: 27770664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Leiden, G20210A mutations in prothrombin gene and antiphospholipid antibodies in systemic lupus erythematosus and antiphospholipid syndrome].
    Reshetniak TM; Patrushev LI; Stukacheva EA; Miroshnikov AI; Tikhonova TL; Nasonov EL; Alekberova ZS
    Ter Arkh; 2000; 72(5):34-8. PubMed ID: 11109617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.
    Chaturvedi S; Braunstein EM; Yuan X; Yu J; Alexander A; Chen H; Gavriilaki E; Alluri R; Streiff MB; Petri M; Crowther MA; McCrae KR; Brodsky RA
    Blood; 2020 Jan; 135(4):239-251. PubMed ID: 31812994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis of antiphospholipid syndrome: recent insights and emerging concepts.
    Lackner KJ; Müller-Calleja N
    Expert Rev Clin Immunol; 2019 Feb; 15(2):199-209. PubMed ID: 30412684
    [No Abstract]   [Full Text] [Related]  

  • 29. VWF, Platelets and the Antiphospholipid Syndrome.
    Huang S; Ninivaggi M; Chayoua W; de Laat B
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic risk factors of thrombosis in the antiphospholipid syndrome.
    Castro-Marrero J; Balada E; Vilardell-Tarrés M; Ordi-Ros J
    Br J Haematol; 2009 Nov; 147(3):289-96. PubMed ID: 19659549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathophysiology of thrombosis and potential targeted therapies in antiphospholipid syndrome.
    Amengual O; Atsumi T; Koike T
    Curr Vasc Pharmacol; 2011 Sep; 9(5):606-18. PubMed ID: 21692741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I.
    Ioannou Y; Zhang JY; Qi M; Gao L; Qi JC; Yu DM; Lau H; Sturgess AD; Vlachoyiannopoulos PG; Moutsopoulos HM; Rahman A; Pericleous C; Atsumi T; Koike T; Heritier S; Giannakopoulos B; Krilis SA
    Arthritis Rheum; 2011 Sep; 63(9):2774-82. PubMed ID: 21618459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk assessment in patients with antiphospholipid antibodies.
    Bertero M; Kuzenko A
    Minerva Med; 2013 Dec; 104(6):639-48. PubMed ID: 24316917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome.
    De Craemer AS; Musial J; Devreese KM
    J Thromb Haemost; 2016 Sep; 14(9):1779-87. PubMed ID: 27314634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is known about pediatric antiphospholipid syndrome?
    Meroni PL; Argolini LM; Pontikaki I
    Expert Rev Hematol; 2016 Oct; 9(10):977-85. PubMed ID: 27615277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome.
    Manganelli V; Truglia S; Capozzi A; Alessandri C; Riitano G; Spinelli FR; Ceccarelli F; Mancuso S; Garofalo T; Longo A; Valesini G; Sorice M; Conti F; Misasi R
    Front Immunol; 2019; 10():460. PubMed ID: 30923525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?
    Ghirardello A; Doria A; Ruffatti A; Rigoli AM; Vesco P; Calligaro A; Gambari PF
    Ann Rheum Dis; 1994 Feb; 53(2):140-2. PubMed ID: 8129460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.
    Otomo K; Atsumi T; Amengual O; Fujieda Y; Kato M; Oku K; Horita T; Yasuda S; Koike T
    Arthritis Rheum; 2012 Feb; 64(2):504-12. PubMed ID: 21953404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway.
    Yasuda S; Bohgaki M; Atsumi T; Koike T
    Immunobiology; 2005; 210(10):775-80. PubMed ID: 16325497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.